

Does Viatris have an access strategy?

Our business and operating model is deliberately designed and implemented to deliver on our strategy to build and sustain access to medicine at scale. Underpinned by Viatris' relevance and success in meeting evolving healthcare needs, we seek to create value for and together with our key stakeholders – the people who trust our medicines every day, the health systems who rely on us, the people who make up Viatris, our partners and the investors who believe in our ability to execute on our ambitious mission.

We are convinced that patients and systems around the world are best served by a healthcare company applying a well-rounded and long-term approach, maintaining viability while working to manage inherent risks and opportunities and continuously striving to advance sustainable operations and responsible practices in a focused way.

Access to medicine begins with sustainably delivering high-quality medicines and health solutions at scale to people, regardless of geography or circumstance. Viatris was formed to bridge the traditional divide between generics and brands, combining the best of both, to address healthcare needs more holistically globally. With an extensive portfolio of medicines to meet nearly every health need, a one-of-a-kind global supply chain designed to reach more people with health solutions when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access is central to everything we do.

We are focused on meeting individual needs, whether with a generic medicine, an improved version of an existing medicine, or a truly novel therapeutic solution. We go beyond developing, making and distributing high-quality medicines and work to help find solutions that support resilient systems for healthcare. We have designed our global operations and supply chain to be a reliable and flexible partner for access across the world, constantly adapting to an ever-evolving landscape.

Our Access and Health Goals

Goal: Provide ARV therapy equivalent to a total of 30 million patients, including more than 2 million children living with HIV/AIDS, between 2022 and the end of 2025.

Our Progress: In 2022, we made progress toward our goal by providing treatments for approximately 8 million patients, including almost 600,000 children living with HIV/AIDS.

Goal: Impact 100 million patients via HCP education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025.

Our Progress: More than 19,000 individuals have an NCD Academy account, representing approximately 48.6 million patients impacted².

²Patient reach calculated by multiplying the number of HCP learners by the average number of patients treated, as self-reported by HCP learners upon registering for NCD Academy. Patient reach includes unique patients as well as repeat patient encounters. As of January 2023.

Partnerships and collaborations are critical, as are policies and strong healthcare systems that allow for healthy competitive environments. The needs are universal, and we work with an array of organizations - globally, regionally, locally, public and private - to support sustainable access to medicines at consistent quality standards. Through our GLOBAL HEALTHCARE GATEWAY® we connect more people with even more products and services to advance access and health. Ultimately, we know we are stronger together, working collaboratively and relentlessly across our company and with the broader global community, in pursuit of access.

Our Portfolio and Reach in 2022:

- Served ~1 billion patients globally¹
- Sold > 80 billion doses of medicine across > 165 countries and territories
- Reached ~ 90% of low- and lower-middle income countries
- Had >250 products on the WHO EML and 62 products on the WHO PreQ List
- Provided products that treat the top 10 of the WHO's leading causes of death globally
- Locally available medicines addressed at least half of the top ten local causes of death, across all country income bands, in >100 countries

¹ The number of patients served is an estimate calculated using internal sales data (global volume of doses sold in 2022 in all markets as aligned with IQVIA standard units), divided by estimated per patient usage, which is based on treatment dose, treatment duration, and treatment adherence as estimated by Viartis Medical Affairs based on approved label indication and instructions for use, current international guideline recommendations, and common usage in clinical practice. Patients using multiple Viartis medicines may be counted as multiple patients. Certain adjustments were applied in consideration of announced divestitures and to account for acceptable alternatives to the patient usage factors noted above, and rounded to the nearest hundred million. Estimates may be subject to reassessment.

For more comprehensive description, see our [2022 Sustainability report](#).